IDEXX Laboratories Inc (US.IDXX)
Capital Allocation Audit · Period: 2010 – 2026
Key Metrics
US.IDXX · YoY: 2026 Q1 vs 2025 Q1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 87.3% | → |
| ROE | 17.9% | ↑ |
| Cash Conversion | 95.6% | → |
| D/E Ratio | 0.71 | → |
| Gross Margin | 63.4% | → |
US.IDXX (IDEXX Laboratories Inc) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY --------------------------- FCF Conversion 87.3% → ROE 17.9% ↑ Cash Conversion 95.6% → D/E Ratio 0.71 → Gross Margin 63.4% →
Key Metrics
US.IDXX (IDEXX Laboratories Inc) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY---------------------------FCF Conversion 87.3% →ROE 17.9% ↑Cash Conversion 95.6% →D/E Ratio 0.71 →Gross Margin 63.4% →Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies